Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.
The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.
Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.
The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.
Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.
Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.
For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.
Intellia Therapeutics (NASDAQ:NTLA) announced the treatment of the first patient with NTLA-2001, a revolutionary potential therapy for transthyretin amyloidosis (ATTR). This groundbreaking single-course therapy utilizes CRISPR technology to potentially halt and reverse disease progression. The Phase 1 study focuses on hereditary ATTR with polyneuropathy, aiming for future trials across broader ATTR patient groups. Intellia's robust plans include rapid movement to pivotal studies, establishing NTLA-2001 as a leading candidate in curative treatments for ATTR.
Intellia Therapeutics (NTLA) announced significant progress in its clinical programs, notably the initiation of a Phase 1 trial for NTLA-2001, targeting transthyretin amyloidosis (ATTR), with patient dosing expected by year-end 2020. The company also aims to submit IND applications for NTLA-5001 (acute myeloid leukemia) in 1H 2021, and NTLA-2002 (hereditary angioedema) in 2H 2021. Financially, Intellia ended Q3 2020 with $407.9 million in cash, marking a healthy increase from the previous year, despite a net loss of $27.8 million. Collaboration revenue rose significantly, driven by the Regeneron partnership.
Intellia Therapeutics (NASDAQ:NTLA) will present its Q3 2020 financial results and operational highlights on November 5, 2020, at 8 a.m. ET. Interested participants can join the call by dialing 1-877-317-6789 in the U.S. or 1-412-317-6789 internationally. A replay will be available post-call on the company's website from 12 p.m. ET the same day. Intellia is focused on developing curative therapeutics using CRISPR/Cas9 technology, aiming to revolutionize medicine by permanently editing disease-related genes with a single treatment.
Intellia Therapeutics (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application to commence a Phase 1 study of NTLA-2001, targeting hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). This therapy, potentially the first curative treatment for ATTR, utilizes in vivo CRISPR/Cas9 technology. The trial aims to assess safety, pharmacokinetics, and efficacy, with expectations to dose the first patient by the end of 2020. Intellia plans to expand the study after determining the optimal dose and further regulatory applications in other countries.
Intellia Therapeutics' co-founder, Dr. Jennifer Doudna, has been awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR/Cas9 genome editing technology, alongside Dr. Emmanuelle Charpentier. This milestone marks the first instance of two women jointly winning this accolade in Chemistry. Intellia’s leadership highlighted the transformative potential of CRISPR/Cas9 in addressing genetic diseases and cancer. The company underscores its commitment to utilizing this groundbreaking tool to develop enduring therapeutic solutions for complex health conditions.
Intellia Therapeutics (NASDAQ: NTLA) has appointed John F. Crowley to its Board of Directors, bringing extensive biotech experience, particularly in rare diseases. Crowley, CEO of Amicus Therapeutics, has a strong track record in transitioning programs from preclinical to clinical stages. His insights as a parent advocate for Pompe disease will be valuable as Intellia embarks on its first clinical trial this year. Meanwhile, Perry Karsen will step down from the board effective December 31, 2020, after five years of significant contributions to the company's growth.
Intellia Therapeutics (NASDAQ: NTLA) will present at Baird’s 2020 Virtual Global Healthcare Conference on September 9, 2020, at 10:50 a.m. ET. The presentation will showcase the company's advancements in CRISPR/Cas9 technology aimed at developing curative therapeutics. A live webcast can be accessed on the company's website, with a replay available for 14 days post-event. Intellia focuses on editing disease-associated genes to treat cancer and immunological diseases, positioning itself as a leader in genome editing.
Intellia Therapeutics (NTLA) has submitted its first regulatory application to the U.K.’s MHRA for a Phase 1 study of NTLA-2001, targeting transthyretin amyloidosis, aiming to dose the first patient by year-end. The company expanded its collaboration with Regeneron, receiving $100 million to co-develop hemophilia treatments. Intellia plans to submit INDs for NTLA-5001 (acute myeloid leukemia) and NTLA-2002 (hereditary angioedema) in 2021. As of June 30, 2020, the company reported a cash position of $436.8 million, enabling operations for at least 24 months.
Intellia Therapeutics (NASDAQ: NTLA) will present its second quarter 2020 financial results and operational highlights in a conference call scheduled for August 6, 2020, at 8 a.m. ET. The company, a frontrunner in genome editing using CRISPR/Cas9 technology, aims to develop curative therapeutics both in vivo and ex vivo. Interested participants can join the call by dialing the provided numbers or access a replay on the company's website later that day. Intellia's commitment to advancing CRISPR technology positions it for significant therapeutic applications.
Intellia Therapeutics (NTLA) has successfully completed an underwritten public offering of 6,301,370 shares at $18.25 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an option for an additional 821,917 shares. Goldman Sachs, Jefferies, and SVB Leerink served as joint book-running managers. The shares were offered under a previously filed shelf registration statement, and a final prospectus supplement detailing the offering was filed with the SEC on June 3, 2020.
FAQ
What is the current stock price of Intellia Therapeutics (NTLA)?
What is the market cap of Intellia Therapeutics (NTLA)?
What is the mission of Intellia Therapeutics?
What diseases is Intellia targeting with their CRISPR-based therapies?
What are Intellia's key advancements in hereditary angioedema (HAE) treatment?
When was Intellia Therapeutics founded?
Who are Intellia's key collaborators?
What is CRISPR/Cas9?
How does Intellia's in vivo program work?
What are the recent financial highlights of Intellia Therapeutics?
What is the scope of Intellia's collaboration with ReCode Therapeutics?
Where can I find more information about Intellia Therapeutics?
